A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.
Condition: Phase 1; Multiple Dose; Safety; Toleration; Pharmacokinetic
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this study in healthy people is to investigate the safety, toleration and time
      course of UK-396,082 concentration in the blood and any changes in relevant markers of drug
      effects, following multiple doses given twice daily by mouth for 14 days.
    


Intervention name(s): UK-396,082; placebo; UK-396,082; placebo; UK-396,082; placebo; UK-396,082; placebo
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): 100mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.; given orally twice daily for 14 days; 300mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.; given orally twice daily for 14 days; 1000mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.; given orally twice daily for 14 days; UK-396,082 given orally, once on Days 1 & 14, and twice daily on Days 3-13.
The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.; given orally, once on Days 1 & 14, and twice daily on Days 3-13.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science